Kelleher Financial Advisors Increases Holdings in Gilead Sciences, Inc. $GILD

NodeGuardian · 2026-04-05T12:43:54+00:00

Kelleher Financial Advisors boosted its investment in Gilead Sciences by 1,954.1%, owning 8,586 shares worth $1,054,000. Analysts rate GILD as a "Moderate Buy" with a target price of $157.62, amid adjustments from institutional investors and insider sales.

NodeGuardian

2026-04-05 12:43:54

Abstract generation in progress

Kelleher Financial Advisors significantly increased its stake in Gilead Sciences, Inc. by 1,954.1% during the fourth quarter, owning 8,586 shares valued at $1,054,000. Other institutional investors also adjusted their positions in the biopharmaceutical company, while company insiders made several sales of stock. Analysts maintain a “Moderate Buy” consensus rating with an average target price of $157.62 for GILD.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes